Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Pande

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 26, 2023
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory DiseaseUlf Müller-Ladner, Axel Dignass, Karl Gaffney, et al.
Rheumatology (Oxford, England)|October 3, 2017
Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?Fowzia Ibrahim, Beatriz Lorente-Cánovas, Caroline J Doré, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 7, 2014
Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patientsThomas G Hammond, Xiaoli Meng, Rosalind E Jenkins, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 26, 2023
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory DiseaseUlf Müller-Ladner, Axel Dignass, Karl Gaffney, et al.
Rheumatology (Oxford, England)|October 3, 2017
Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?Fowzia Ibrahim, Beatriz Lorente-Cánovas, Caroline J Doré, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 7, 2014
Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patientsThomas G Hammond, Xiaoli Meng, Rosalind E Jenkins, et al.
Pageof 2